ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Published Date: 06 Jun 2025

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone, according ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

2.

Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

3.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

4.

investigating radiation oncology applications of artificial general intelligence.

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot